Ixekizumab

MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.

Ixekizumab was associated with greater efficacy than etanercept in a cohort of European patients with moderate to severe psoriasis, regardless of reimbursement criteria in the country where the patient was treated, according to a study.

Patients with psoriasis who were treated with ixekizumab were more likely to adhere to therapy compared with those treated with adalimumab over a 24-month period, according to a study.

Ixekizumab demonstrates a safety and tolerability profile that is “reassuring” and consistent with previous studies in patients with psoriatic arthritis, according to researchers.

Pediatric patients with moderate to severe psoriasis experienced encouraging efficacy and safety outcomes through 108 weeks of treatment with ixekizumab, according to a study.

Early response to ixekizumab or ustekinumab was associated with stable, long-term response in moderate to severe psoriasis, according to a study.

Most patients with active, radiographic axial spondyloarthritis who receive ixekizumab for 2 years show no radiographic disease progression, with low mean progression overall, according to a poster presentation at the EULAR 2021 Congress.

Ixekizumab is efficacious in patients with psoriatic arthritis for up to 1 year, with or without concomitant methotrexate use, according to data published in Arthritis Research & Therapy.

Strong data for two interleukin-17 inhibitors have given a lift to clinicians treating the spondyloarthropathies, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.